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Abstract
Background: The dismal overall survival (OS) prognosis of glioblastoma, even after trimodal therapy, can be
attributed mainly to the frequent incidence of intracranial relapse (ICR), which tends to present as an in-field
recurrence after a radiation dose of 60 Gray (Gy). In this study, molecular marker-based prognostic indices were
used to compare the outcomes of radiation with a standard dose versus a moderate dose escalation.
Methods: This retrospective analysis included 156 patients treated between 2009 and 2016. All patients were
medically fit for postoperative chemoradiotherapy. In the dose-escalation cohort a simultaneous integrated boost
of up to 66 Gy (66 Gy RT) within small high-risk volumes was applied. All other patients received daily radiation to
a total dose of 60 Gy or twice daily to a total dose of 59.2 Gy (60 Gy RT).
Results: A total of 133 patients received standard 60 Gy RT, while 23 received 66 Gy RT. Patients in the 66 Gy
RT group were younger (p < 0.001), whereas concomitant temozolomide use was more frequent in the 60 Gy
RT group (p < 0.001). Other intergroup differences in known prognostic factors were not observed. Notably,
the median time to ICR was significantly prolonged in the 66 Gy RT arm versus the 60 Gy RT arm (12.2 versus
7.6 months, p = 0.011), and this translated to an improved OS (18.8 versus 15.3 months, p = 0.012). A multivariate analysis
revealed a strong association of 66 Gy RT with a prolonged time to ICR (hazard ratio = 0.498, p = 0.01) and OS
(hazard ratio = 0.451, p = 0.01). These differences remained significant after implementing molecular marker-
based prognostic scores (ICR p = 0.008, OS p = 0.007) and propensity-scored matched pairing (ICR p = 0.099,
OS p = 0.023).
Conclusion: Radiation dose escalation was found to correlate with an improved time to ICR and OS in this
cohort of glioblastoma patients. However, further prospective validation of these results is warranted.
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Background
The field of glioblastoma (GBM) treatment has seen little
progress since the implementation of temozolomide
(TMZ) and the establishment of trimodal therapy, which
comprises surgery, adjuvant radiation with concurrent
TMZ and TMZ maintenance, as standard therapy for
medically fit patients by Stupp and colleagues in 2005 [1].
Tumor treating fields (TTF) during maintenance TMZ
therapy have been shown to further improve patient out-
come in a phase III trial compared to standard trimodal
therapy [2]. However due to reimbursement issues and a
potential negative impact on quality of life the addition of
TTF is not yet nationwide standard of care. Currently, a
standard total radiation dose of 60Gy is administered via
single-dose fractionated radiotherapy in 2-Gy fractions
concomitantly with TMZ. However, this standard is based
on older studies of adjuvant radiotherapy alone in which a
dose-response relationship was identified for doses up to
60Gy [3, 4].
GBM is considered a radioresistant malignancy, and
most patients die from local, intracranial relapse. There-
fore, radiotherapeutic dose escalation strategies have
long been a topic of interest. Studies of patients treated
with 2-dimensional (2D) or 3D planed radiotherapy
during the pre-TMZ era reported that doses exceeding
60 Gy did not yield survival benefits; rather, patients
faced an increased risk of radiation-induced brain necrosis
[4, 5]. However, modern radiation techniques could po-
tentially allow dose escalation within smaller high-risk
regions with lower dose accumulations in surrounding
normal brain tissues, thus decreasing the risk of symp-
tomatic brain necrosis [6]. Several more recent studies
on state-of the art dose-escalation have reported inconclu-
sive results. One phase I study demonstrated the feasibility
of dose escalation via intensity modulated radiotherapy
(IMRT) without concurrent TMZ [7], while another re-
ported promising results with a radiation dose escalation
up to 81Gy via IMRT with concomitant TMZ [8]. A
phase-I/II study with a carbon ion boost suggested an
association of improved progression-free survival and
OS with higher carbon boost doses [9]. However, a pro-
spective phase II study and several retrospective analyses
of radiation dose escalations > 60Gy with concomitant
TMZ did not find substantial improvements in overall
survival (OS) [10–12]. Accordingly, 60 Gy remains the
standard radiation dose.
The conflicting findings of prior studies might be
attributable to the wide variety in clinical outcome and
treatment response of histologically confirmed GBM
after radiotherapy and TMZ. These differences can only
be partially explained by established baseline characteris-
tics of patient, tumor and surgical resection status [13].
Accordingly, genetic alterations and molecular markers
are considered important, with a high prognostic impact.
Of these, O(6)-methylguanine DNA methyltransferase
(MGMT) promoter methylation is likely the best known
molecular marker [14]. Several other molecular param-
eters, such as isocitrate-dehydrogenase (IDH), have
been identified. Accordingly, GBM is among the first
cancers with a molecular rather than classical histological
classification [15–17].
Recently, MGMT and IDH were used together with
other known prognostic factors to identify subgroups of
GBM patients with significantly different treatment
outcomes after standard trimodal treatment [18]. The
current study aimed to investigate whether a moderate
state-of-the-art radiation dose escalation would correlate
with an improved survival outcome in patients stratified
according to these novel molecular markers.
Methods
Surgical treatment and radiation dose prescription
This retrospective analysis included patients treated
between January 2009 and October 2016. All treatment
decisions were made by an interdisciplinary tumor
board.
In the standard group radiotherapy was adminis-
tered in 2-Gy fractions to a total dose of 60 Gy or
twice-per-day (BID) in 1.6 Gy fractions to a total dose
of 59.2 Gy. These two regimens have been described
in detail elsewhere and were proven to be equally ef-
ficacious in terms of OS and intracerebral failure. Pa-
tients treated with either regimen were combined in a
single group for analysis (abbreviated as 60 Gy RT for
ease of reading) [19].
Patients were offered an experimental regimen in which
moderate dose escalation was achieved via a simultaneous
integrated boost (SIB) to the macroscopic tumor region/
resection cavity. This option was based on earlier in-house
experiences with moderate dose escalation for GBM [5].
These patients received a 66-Gy SIB to the pre-surgical
gross tumor volume (GTV) or residual disease/suspected
residual tumor and 60 Gy to the surrounding planning
target volume (66 Gy RT).
Treatment planning
Computed tomography (CT) with a thermoplastic mask
was performed for RT planning. Additionally, gadolinium-
enhanced magnetic resonance imaging (MRI) was per-
formed before and after surgical resection and registered
rigidly to the planning CT. These MRI scans were used to
delineate the target volumes and organs at risk (OAR).
The GTV was defined as the combined volume of the
postoperative surgical cavity, with or without residual tumor
lesions, and the tumor extension on preoperative T1-
weighted gadolinium-enhanced MRI. Diffusion-weighted
imaging (DWI) findings were also used to estimate the
GTV. The SIB volume comprised the part of the GTV
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identified as either residual disease or potential residual
disease (e.g. eloquent areas or other critical structures
that usually impede radical surgery) and was defined in
collaboration with the respective neurosurgeon. Regarding
the clinical target volume (CTV), a 2-cm symmetrical
margin around the GTV was added with reduced margins
to anatomical boundaries such as bone, tentorium or
falx. For the planning target volume (PTV), an additional
0.2–0.5 cm margin was added (depending on the treat-
ment and modality used for position verification).
IMRT was applied using a 6-MV linear accelerator with
multileaf collimators or the Novalis™ therapy system (Varian,
USA; Brainlab, Heimstetten, Germany). Some patients were
treated using helical tomotherapy. For all patients except
those undergoing tomotherapy, treatment comprised either
step-and-shoot IMRT or volumetric arc therapy.
Assessment of prognostic factors, toxicities and follow-up
According to a previous publication, patients were classi-
fied into prognostic groups (RPA [recursive partitioning
analysis] class 1, 2 or 3), which were determined based on
KPS, completeness of resection, IDH and MGMT status
and age, as described elsewhere in detail [18]. Patient files
were screened retrospectively for the analysis of toxicities,
which were usually scored weekly during treatment ac-
cording to the common toxicity criteria for adverse events
(CTCAE) 4.0. Follow-up consisted of clinical and MRI ex-
aminations every 2–3months. Additional amino acid posi-
tron emission tomography (PET) scans were performed if
the MRI investigations were inconclusive.
Statistical analyses and software
The patient and tumor characteristics were compared
between the two treatment groups using the chi-squared
test (categorical variables) or Mann–Whitney U test
(continuous variables). The Kaplan–Meier method was
used to calculate the OS and intracranial control (ICC)
probabilities from the day of surgery, and the log-rank
test was used for intergroup comparisons of these probabil-
ities. Univariate and multivariate analyses were performed
using Cox regression analyses; here, parameters with signifi-
cance according to the univariate analysis (p < 0.05) were
included in the multivariate analysis. Propensity-scored
matching (PSM) was performed using the nearest-neighbor
matching method with a caliper of 0.4 and matching ratio
of 1:2 (dose escalation versus no dose escalation). All statis-
tical analyses were performed using SPSS version 24.0 (IBM
Inc., Armonk, NY, USA) and R version 3.2.5 (R Foundation
for Statistical Computing, Vienna, Austria) [20].
Results
Table 1 presents the baseline characteristics for both
treatment groups. The patients receiving standard doses
and dose escalation differed significantly in terms of age,
with a median age of 51 years in the 66 Gy RT versus 62
years in the 60 Gy RT group (p < 0.001). In contrast, the
RPA class and resection completeness did not differ
between the groups. Patients in the 60Gy RT group more
frequently received concomitant TMZ (p < 0.001) and
had a slightly larger PTV volumes.
In the experimental patient cohort, the median SIB
volume was 19.2 cm3 (ccm, range: 2.6–83.6 cm3). Dose
escalation within a small volume was generally well
tolerated, as indicated by a lack of differences in acute
toxicity between the 60 Gy RT and 66 Gy RT groups.
Additional file 1: Table S1 summarizes the observed
acute toxicities within the 66 Gy RT group. Although
none of these patients developed symptomatic radiation-
induced brain necrosis, follow-up MRI revealed asymp-
tomatic brain necrosis in one patient, who was referred
Table 1 Patient and tumor characteristics
66 Gy RT (n = 23) 60 Gy RT (n = 133) p-value
Sex
Female 12 (52.2%) 44 (33.1%) 0.172
Male 11 (47.8%) 89 (66.9%)
Median age (years) 51 62 < 0.001
Tumor location
Frontal 8 (34.8%) 42 (31.6%) 0.692
Parietal 5 (21.7%) 32 (24.1%)
Temporal 4 (17.4%) 39 (29.3%)
Occipital 2 (8.7%) 9 (6.8%)
Central 3 (13.0%) 9 (6.8%)
Multifocal 1 (4.3%) 2 (1.5%)
Resection status
Gross total 8 (34.8%) 54 (40.9%) 0.588
Subtotal 13 (56.5%) 60 (45.5%)
Biopsy 2 (8.7%) 18 (13.6%)
RPA class
1 2 (8.7%) 14 (10.5%) 0.682
2 12 (52.2%) 74 (55.6%)
3 3 (13.0%) 8 (6.0%)
n.a. 6 (26.1%) 37 (27.8%)
MGMT
Methylated 11 (47.8%) 43 (32.3%) 0.163
Unmethylated 6 (26.1%) 63 (47.4%)
n.a. 6 (26.1%) 27 (20.3%)
PTV ml (Average) 293 357 < 0.001
Concurrent temozolomide
Yes 18 (78.3%) 129 (97.0%) < 0.001
No 5 (21.7%) 4 (3.0%)
RT radiotherapy, RPA Recursive partitioning analysis, n.a. not available, MGMT
O(6)-methylguanine DNA methyltransferase, PTV planning target volume
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for a histological exclusion of relapse. The biopsy con-
firmed radionecrosis with no signs of tumor recurrence.
Regarding survival, the median OS durations were 15.3
months (range 2 to 48.1months) in the 60Gy RT group and
18.8months (range: 5 to 37.8months) in the 66Gy RT
group, and the median intervals to intracranial relapse were
7.6 (range: 0.3 to 30.8months) and 12.2 (range: 3.5 to 37.4)
months, respectively. Both differences were significant, as
shown in Fig. 1. To rule out confounding errors an add-
itional comparison of the experimental cohort with the nor-
mofractionated cohort was performed. This analysis also
confirmed the significant benefit regarding OS (p = 0.009)
and intracranial relapse (p= 0.015) for patients treated with
66Gy RT (Additional file 2: Figure S1). The RPA classifica-
tion revealed a non-significant difference according to RPA.
Additional file 3: Figure S2 depicts the corresponding
Kaplan–Meier survival curves for the whole cohort. An add-
itional analysis stratified by RPA group revealed increases in
the durations of OS and ICC in the 66Gy RT group relative
to other groups (p= 0.007 for OS and p= 0.008 for ICC).
Figure 2 and Additional file 4: Figure S3 present the
Kaplan–Meier curves for OS and ICC by RPA class.
In the univariate analysis of factors related to OS, dose
escalation correlated with an increase in OS [hazard ratio
(HR) = 0.47, range: 0.26–0.86, p = 0.007], whereas a higher
age (HR = 1.02, range: 1.001–1.04, p = 0.03) and worse
resection status (HR = 1.36, range: 1.02–1.80, p = 0.04)
were associated with a decreased OS. Furthermore, an
inverse trend was observed between the RPA class and
OS (HR = 1.18, range: 0.98–1.42, p = 0.07). Dose escalation
(p = 0.023) and resection status (p = 0.028) remained
significantly associated with OS in the multivariate ana-
lysis. A further univariate analysis of factors affecting ICC
revealed strong associations with an escalated radiation
dose (HR = 0.51, range: 0.30–0.87, p = 0.007) and resection
status (HR = 1.35, range: 1.03–1.77, p = 0.031). Both
factors remained significantly associated with ICC in
the multivariate analysis (p = 0.010 and 0.021, respect-
ively). Table 2 summarizes the results of the univariate
and multivariate analyses.
To exclude bias associated with the retrospective study
design, 142 patients with fully available data were sub-
jected to an additional PSM analysis of the following
matching parameters: age, tumor location, resection
type, TMZ use and RPA class (which additionally imple-
mented information about the KPS and IDH and MGMT
statuses). Here, the PSM revealed a significant difference
in OS between the 66Gy RT and 60Gy RT groups (p =
0.023), while the 66Gy RT group exhibited a trend towards
better ICC (p = 0.099). Figure 3 presents the Kaplan-Meier
plots for the propensity-matched patients. Additional file
5: Table S2 presents patient and tumor characteristics after
propensity scored matching.
Discussion
This report describes the initial experiences with state-
of-the-art radiation dose escalation via a SIB approach in
GBM patients stratified by molecular prognostic markers.
Although the study was limited by its retrospective design,
we attempted to reduce the associated bias through
stratification according to molecularly defined prognos-
tic groups and a PSM analysis, which both confirmed
Fig. 1 Probabilities of intracranial control (left) and overall survival among patients receiving a standard radiation dose (60 Gy radiotherapy [RT])
and those receiving dose-escalated radiotherapy (66 Gy RT). Median time to intracranial relapse: 225 days (60 Gy) versus 289 days (66 Gy),
p = 0.011. Median OS: 397 days (60 Gy) versus 533 days (66 Gy), p = 0.012
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the initial finding that moderate dose escalation within
small high-risk volumes yielded significant improvements
in OS and ICC. Furthermore, this survival benefit was
maintained when patients were grouped according to
established prognostic groups based mainly upon the
MGMT and IDH status. Nonetheless even RPA classifica-
tion might not be able to completely rule out misbalances
between the two treatment groups, especially as patients in
the 66Gy RT group showed a tendency towards a higher
rate of MGMT promoter methylation. Additionally other
potentially prognostic factors such as the exact anatomical
tumor location [21–23] microRNA profile [24, 25], neutro-
phil to lymphocyte ratio [26] and functional imaging pa-
rameters [27] were not considered for risk stratification.
We additionally did not assess other potential confounders
such as the postoperative waiting period, although a large
retrospective analysis of GBM patients revealed that this
factor had no impact on patient survival [28]. Furthermore,
we did not analyze the concomitant use of corticosteroid
therapy, which may have a detrimental effect on OS [29].
Still, we note that this potential association remains contro-
versial and is not proven by prospective data.
Fig. 2 Overall survival probabilities of patients receiving a standard radiation dose (60 Gy radiotherapy [RT]) and those receiving dose-escalated
radiotherapy (66 Gy RT) after stratification by recursive partitioning analysis (RPA) prognostic groups 1–3, n.a. = insufficient data for allocation. p =
0.007 for OS and p = 0.008 for ICC pooled according to RPA classification
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Although the groups in our study differed slightly with
respect to age, the observed improvements in ICC and
OS were not likely attributable to this difference.
Patients receiving standard-dose radiation had a median
OS of 15.3months, which was consistent with the OS
reported by Stupp for the chemoradiotherapy arm
(14.6 months) [1]. Furthermore, although patients in
the 66 Gy RT arm were younger, concomitant TMZ use
was less frequent in this group, mainly because of
comorbidities or a poorer KPS. We further note that
the radiation techniques did not differ between the
groups: all patients received IMRT, which is potentially
Table 2 Univariate and multivariate Cox regression analyses of OS and ICC
Univariate Analysis Multivariate Analysis
HR (range) P-value HR (range) P-value
OS
Age 1.020 (1.001–1.039) 0.034 1.015 (0.996–1.035) 0.121
Dose escalation 0.472 (0.259–0.858) 0.014 0.494 (0.269–0.906) 0.023
Localization 1.064 (0.924–1.225) 0.387
Resection status 1.338 (1.009–1.772) 0.043 1.369 (1.035–1.811) 0.028
No Temozolomide 1.421 (0.624–3.232) 0.403
RPA Class 1.183 (0.982–1.424) 0.077
PTV (ml) 1.000 (0.999–1.001) 0.542
ICC
Age 1.007 (0.991–1.023) 0.423
Dose escalation 0.512 (0.302–0.866) 0.013 0.498 (0.294–0.844) 0.010
Localization 1.124 (0.976–1.295) 0.105
Resection status 1.344 (1.032–1.750) 0.028 1.365 (1.047–1.780) 0.021
No Temozolomide 1.857 (0.866–3.983) 0.112
RPA 1.062 (0.891–1.267) 0.502
PTV (ml) 1.000 (1.000–1.001) 0.304
OS overall survival, ICC intracranial control, HR hazard ratio, RPA recursive partitioning analysis; resection status was classified as gross total resection, partial
resection or biopsy
Fig. 3 Probabilities of intracranial control (left) and overall survival patients receiving a standard radiation dose (60 Gy radiotherapy [RT]) and
those receiving dose-escalated radiotherapy (66 Gy RT) after propensity-scored matching. Median OS: 457 days (60 Gy) versus 535 days (66 Gy),
p = 0.023. Median time to intracranial relapse: 225 days (60 Gy) versus 301 days (66 Gy), p = 0.09
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superior to 3D conformal radiotherapy [30]. Another
difference is the PTV which was slightly larger in the
60 Gy RT group. This could mean that patients within
the 66 Gy RT group presented smaller tumors, which is
a potential confounder. However all but two patients in
the 66 Gy RT were treated with high precision radiation
therapy (Novalis) with reduced CTV-PTV margins (2mm
instead of 5mm). Therefore the small (absolute) difference
of PTVs might most likely be due to these circumstances
and was therefore not confounding the results. This is
supported by univariate analyses on OS and ICC that did
not show an association with PTV volume.
Although GBM cells, and particularly GBM stem cells, are
generally considered radioresistant [31], a dose-response
relationship has been identified for these tumors [32, 33].
Therefore, efforts to improve therapeutic outcomes should
include radiation dose escalation, among other strategies.
The Radiation Therapy Oncology Group (RTOG) study
83–02, which was conducted during the pre-TMZ era,
identified a dose-dependency among GBM patients receiv-
ing a hyperfractionated accelerated dose-escalated radiation
schedule [34]. In contrast, the randomized RTOG 93–05
trial did not observe an improved outcome after dose
escalation by a stereotactic boost [35].
In the TMZ era, several studies on the effect of radiation
dose escalation have yielded conflicting results. One
single-arm study reported a median OS of 14.8months
after a dose escalation to 72Gy with an amino acid
PET-based integrated boost. However, that study included
only 22 patients, and therefore the results should be inter-
preted cautiously [10]. In a retrospective analysis, no sig-
nificant survival benefit was observed among 128 patients
receiving dose-escalated radiotherapy when compared to
81 patients receiving a standard radiation dose. In that
analysis, however, the prescribed doses within the esca-
lated arm differed widely (61–76Gy), and the median
2-Gy equivalent dose of 64Gy was relatively low [12].
Another retrospective analysis of 49 patients receiving
dose escalations of up to 70Gy also failed to report a
significant survival benefit relative to a 60-Gy radiation
dose [11]. In that analysis, however, the 60-Gy cohort had
a relatively long OS of 18.4 months. Additionally, a
statistical trend toward improved survival was observed for
patients receiving an escalated dose to the subventricular
zones was found, suggesting that the area of dose escal-
ation is a critical factor in terms of efficacy. Several other
publications highlighted that the dose to the subventricular
zones may be an important factor in terms of outcome
[36, 37]. This was not assessed in our study and is a
potential confounder.
A study on upfront dose escalation by 6 to 14 Gy
Gamma Knife radiotherapy reported very promising OS
results with a median OS time of 23months in a relatively
large cohort of 174 patients [38].
The use of amino acid PET to determine target volumes
for dose escalation appears to be promising. A recent
study of a relatively high PET-based dose escalation re-
ported a median OS of 20.0months [39], and Tsien and
colleagues reported a similarly promising survival out-
come after dose escalation (20.1months) [8]. The neu-
rooncologic community eagerly awaits the results of larger
ongoing studies investigating the association of amino
acid PET tracer uptake with recurrence patterns
(https://clinicaltrials.gov/ct2/show/NCT01873469?
term=NCT01873469&rank=1), as these are expected to
direct future studies of image-guided dose escalation. Ac-
cording to several studies, amino-acid PET-based treatment
planning yields larger high-risk volumes [40] that correlate
more strongly with recurrent disease than MRI-based
delineation [8, 41–43]. Given the prognostic relevance of
the metabolic active tumor volume [27, 44], the selective
dose escalation of PET-defined volumes appears promising.
Conclusion
In conclusion, our data suggest an association of modern
approaches to radiation dose escalation within small
high-risk regions with improved survival in GBM patients.
However, these findings should be interpreted cautiously,
given the retrospective nature of the data. Further
validation through prospective trials, ideally combined
with functional imaging, is warranted.
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